AU Stock MarketDetailed Quotes

PAROA Paradigm Biopharmaceuticals Ltd

Watchlist
  • 0.091
  • -0.002-2.15%
20min DelayTrading May 8 14:30 AET
35.44MMarket Cap0.00P/E (Static)

About Paradigm Biopharmaceuticals Ltd Company

Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulphate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.

Company Profile

SymbolPAROA
Company NameParadigm Biopharmaceuticals Ltd
Founded2014
MarketASX
Employees50
Fiscal Year Ends06-30
Address500 Collins Street Level 15
CityMelbourne
CountryAustralia
Zip Code3000
Phone+61 396295566
Share RegistryAUTOMIC REGISTRY SERVICES Level 5, 126 Phillip Street, SYDNEY, NSW, AUSTRALIA, 2000 02 9698 5414

Company Executives

  • Name
  • Position
  • Salary
  • Paul Rennie
  • Executive Director,Managing Director,Executive Chairman
  • --
  • Matthew James Fry
  • Non-Executive Director
  • --
  • Donna Skerrett
  • Executive Director
  • --
  • Amos Meltzer
  • Non-Executive Director
  • --

Market Insights

Warren Buffett Portfolio Warren Buffett Portfolio

Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.

Unlock Now

Discussing

Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve Show More